United Kingdom
Data processing


CTA requires contrast unless you can see without it.

If the patient journey requires a CTA to view and or track an aortic aneurysm, the IV contrast can be associated with problems such as patient discomfort, allergic reactions, anaphylaxis, kidney injury, etc. along with a second CT scan adding to the radiation dosing.



Our value proposition lies in its ability to replace existing CTA contrast technology with next-generation vascular imaging technology, providing a patient-first approach to arterial studies. AiSentia’s technology eliminates the need for harmful contrast agents, patient IV discomfort, and unnecessary radiation dosing while seamlessly integrating into the current clinical workflow. It allows patients with contrast-induced nephropathy (CIN), renal failure, or anaphylactic reaction to contrast access to CTA scans which roughly represent 2% of the population.


AiSentia can see more than the human eye! Our deep learning driven AI pipelines harness additional information from routine CT scans performed without intravenous contrast injection.


The current top priorities are to start the funding process, to prepare steps for FDA (pre-submission meeting), to identify an American clinical validation partner, and to identify a prototype SW development partner.

Meet the team

Regent Lee portrait

Regent Lee

Inventor & CMO


Alessandro Radaelli

Venture Partner

Alessandro joined NLC in April 2022 and brings over 20 years of experience in the MedTech industry. His passion lies in translating clinical needs into meaningful solutions, building purpose-driven 'tribes' of early adopters and taking impactful innovations from idea to business realisation. He has lived in four European countries and has travelled to more than 20 countries with great curiosity for healthcare systems, and the local food culture.

Seán Walsh

Seán Walsh